Sutro Biopharma (STRO)

• Market cap: $89M
• 1 day: -5.41%
• 5 days: -9.48%
• 1 month: 20%
• 3 months: 25.01%
• 6 months: 20.04%
• Year to date: -45.6%
• 1 year: -70.42%
• 5 years: -92.05%
• 10 years: -93.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 244